@leevalueroach Though I don't see where you said anything bad, it was all very complimentary
Does she have a liberal arts degree? The message was probably lost in translation.
@sentdefender I seem to remember DJT saying that he would never signal to his enemies what he was going to do military wise. Why doesn't this guy shut up for once
@gothburz@LiveinSpirit7 So you listened to the market but in the end got such a small fraction of the market, you couldn't make any money. Sounds like you didn't listen correctly.
@DeeZee84547086@WhiskyMAGA Another B.S. post. You need approval from a doctor and a psychiatrist and have to pass a written exam to own a gun.
https://t.co/i0lputfcr8
@OGquaker@bigpiclongterm@WallStreetMav There are no futures on tomatoes,lettuce,peppers,potatoes,cabbage,sweet corn,onions,garlic,broccoli,spinach,apples,bananas,peaches....
@OGquaker@janelle_pa53662@nettermike Odd that you were able to get into college to flunk it without having a high school diploma( since you say you flunked high school, I assume you didn't graduate).
"Ohhh, noo, $VELO is down 40%, from $26 to $15!"
> In at $9.70
"Ohhhh, noo, $UMAC is down 25%, from $34 to $ 25!"
> In at $13.80
"Ohhhh, noo, $KUYAF is down 40%, from $0.92 to $0.53!"
> In at $0.24
Of course, there are some name I'm down on, too, or just marginally up on. At the moment they are still low, and lows are for buying, and not every low buy will be green right away.
In the future they will be high, and the inevitable pullbacks will look just like the ones above.
It's never it fun giving back gains in those kind of moves...
But there's a big difference between 'compounding less aggressively' and 'losing money', and that difference is bought by your entry.
Scientists have discovered a promising new way to help the immune system detect and attack hidden cancer cells.
A first-in-class drug called GRWD5769 (an oral ERAP1 inhibitor) has shown encouraging early results, shrinking tumors in patients with six different types of advanced cancer: lung, liver, bladder, cervical, head and neck, and colorectal.
In a Phase 1/1b clinical trial (EMITT-1) involving 83 heavily pre-treated patients across multiple countries, tumors shrank in 26 participants. Of those, 15 experienced reductions of at least 30%. Many patients had already failed prior therapies, including immunotherapies.
The drug works by blocking the enzyme ERAP1, which cancers often use to “edit” their surface proteins and evade immune detection. By inhibiting ERAP1, GRWD5769 alters the tumor’s antigen presentation, effectively removing the cancer’s invisibility cloak and making the cells more visible to the immune system. It was tested in combination with the PD-1 inhibitor cemiplimab (Libtayo).
Particularly strong signals were seen in certain hard-to-treat cancers. For example, disease control for at least six months was achieved in 51% of colorectal cancer patients and 55% of lung cancer patients in the expansion cohorts.
While these early results are promising, experts emphasize this is still an early-phase study. Larger trials are needed to confirm efficacy, durability of response, and impact on long-term survival.
If successful, this approach could expand the number of patients who benefit from immunotherapy — which currently works in only about one-third of cases.
[Grey Wolf Therapeutics. “EMITT-1: Clinical and pharmacodynamic activity with the oral ERAP1 inhibitor GRWD5769 and cemiplimab in 6 completed phase 1b expansion cohorts in solid tumors...” Presented at ASCO Annual Meeting, 2026]
A 24-year-old Polish tennis player arrived in Paris last week ranked 114th in the world, with no sponsors, no guaranteed income, and no certainty she could even pay for her hotel room.
She had to win three qualifying matches just to enter the French Open main draw. Prize money is only paid at the end of the tournament, so a Polish sports drink brand quietly stepped in and covered her hotel bill.
Her name is Maja Chwalinska. And today, she plays in the French Open final.
Before this tournament, she had won exactly one Grand Slam main draw match in her entire career. She had battled depression so severe that in 2021 she couldn't get out of bed. She underwent knee surgery in 2022. She spent years grinding through small tournaments across Europe just to stay afloat.
Then she arrived in Paris, won three qualifiers, and kept winning. Zheng Qinwen. Elise Mertens. Maria Sakkari. Diana Shnaider. Nine straight matches. One set dropped.
She is now the first qualifier in French Open history to reach the final. The last time a qualifier reached a Grand Slam final, it was Emma Raducanu at the 2021 US Open. Raducanu won.
By simply making the final, Chwalinska has earned more prize money than her entire career combined. The runner-up cheque alone is $1.6 million. If she wins today, she takes home $3.25 million.
One week ago she couldn't pay for her hotel room.